Association of genetic polymorphisms in genes involved in Ara-C and dNTP metabolism pathway with chemosensitivity and prognosis of adult acute myeloid leukemia (AML)

Table 4 Combined genotypes of RRM2 and E2F1 polymorphisms and chemotherapy sensitivity in AML patients

rs1130609	rs3213150	CR, n (%)	Non-CR, n (%)	P	OR (95% CI)	P ^b	OR (95% CI)^b
TT+GT	CC+CT	158 (66.7%)	79 (33.3%)		1.00 (reference)		1.00 (reference)
TT+GT	TT	20 (54.1%)	17 (45.9%)	0.134	1.700 (0.844–3.426)	0.048	2.115 (1.006–4.450)
GG	CC+CT	13 (48.1%)	14 (51.9%)	0.056	2.154 (0.966–4.802)	0.159	1.840 (0.787–4.301)
GG	TT	1 (16.7%)	5 (83.3%)	0.004	10.00 (1.149–87.06)	0.041	9.780 (1.099–87.069)
Unfavorable combinations^a		34 (48.6%)	36 (51.4%)	0.006	2.118 (1.233–3.637)	0.005	2.257 (1.273–4.002)

^aUnfavorable combination genotypes included rs1130609 GG genotype or rs3213150 TT genotype
^bAdjusted by age, risk stratification, WBC count, and serum LDH level

ISSN: 1479-5876